LRMR
$4.38
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Intraday
Recent News
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
Larimar Therapeutics price target raised to $12 from $11 at Wedbush
Wedbush raised the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $11 and keeps an Outperform rating on the shares. The firm notes that last week, the company completed an upsized $100M offering following receipt of Breakthrough Therapy designation for nomlabofusp in Friedreich’s ataxia. After incorporating the raise, Wedbush is also increasing its Q4 spending to tie with year-end 2025 cash $137M. While the firm acknowledges recent FDA decisions have been a source of concern for
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?
Larimar Therapeutics recently completed an upsized US$100,000,000 follow-on equity offering at US$5.00 per share, shortly after the FDA granted Breakthrough Therapy Designation to its lead Friedreich’s ataxia candidate, nomlabofusp. This combination of expedited regulatory status and fresh capital raises the company’s capacity to advance nomlabofusp toward planned late-stage development and potential approval milestones. Next, we’ll examine how Breakthrough Therapy Designation for...
BC-Most Active Stocks
Nu Holdings Ltd. 64,722,524 16.85
Larimar Therapeutics' Friedreich's Ataxia Therapy Receives FDA Breakthrough Status; Shares Rise
Larimar Therapeutics (LRMR) said Tuesday the US Food and Drug Administration has granted Breakthroug